Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine plus Imiquimod for Bolivian Cutaneous Leishmaniasis
NCT01380314Phase 2Completed
- Sponsor
- FOUNDATION FADER
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cutaneous leishmaniasis (CL) comparing Miltefosine + Imiquimod with Miltefosine + Placebo (2 arms). Primary endpoint: Healing of ulcers at 45 days. Started Mar 2008; status: completed.
02
Drugs
imiquimod
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01380314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380314.